Arif Khan obtained an M.D. degree, graduated from the Bangalore University Medical College and Research Institute (1975), and completed postgraduate training in psychiatry at the Christchurch Clinical School (University of Otago, New Zealand, from 1977 to 1981) and at the University of Connecticut, USA, from 1981 to 1984. Khan is licensed to practice medicine by the Indian Medical Council (Karnataka state) and in the State of Washington, USA. He is a Member of the American Medical Association and a Fellow of the American Psychiatric Association and has been a Board Member of the American College of Clinical Psychopharmacology since 2006. His research interests include psychopharmacology, clinical trial design features, and clinical treatment of psychiatric disorders with emphasis on major depressive disorder and the prevention of suicide. Since 1980, Khan has authored about 200 medical journal publications and conference presentations at psychiatry meetings. Khan is currently the Medical Director of the Northwest Clinical Research Center where he has presided as a Principal Investigator of over 332 clinical trials. Khan is also an Adjunct Professor of psychiatry at the Duke University School of Medicine, USA, since 2005. He has been involved in the development of novel psychopharmacology compounds for the treatment of mood disorders, chronic pain, suicide prevention, and PTSD by founding two new pharmaceutical companies (Columbia NW Pharmaceuticals and Rhine Pharmaceuticals) since 2010.
Biography Updated on 26 August 2012